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Summary Zinc(II) phthalocyanine, a hydrophobic photosensitiser, was incorporated in unilamellar liposomes
and studied in vivo for fluorescence kinetics and photodynamic activity. An observation chamber mounted in a
dorsal skinfold of female WAG/Rij rats was used as a model system. In the chamber, an isogeneic mammary
carcinoma was transplanted in the subcutaneous tissue. Phthalocyanine fluorescence was excited at 610 nm
with a power density of 0.25 mW cm-2 and was detected above 665 nm through a high-pass filter using a
two-stage image intensifier coupled to a charge-coupled device (CCD) camera. Following i.v. administration of
0.14mgkg-' of the drug, the fluorescence pharmacokinetics of the dye in vasculature, normal tissue and
tumour tissue was determined as a function of time. Tumour fluorescence increased slowly to a maximum
about 3 h post injection (p.i.), and remained well above the normal tissue fluorescence till 24 h p.i.
Fluorescence in the circulation was always stronger than in the tissues. A treatment light dose at a wavelength
of 675 nm was delivered 24 h p.i. One group of six animals received a total light dose of 150 J cm-2
(100 mW cm-2). A second group of six animals received a total light dose of450 J cm-2 at the same dose rate.
Vascular damage resulting from treatment was observed only at the final stages of the irradiation, despite the
relatively high levels of fluorescence in the circulation. Immediate post-treatment (re)transplantation of the
content of the chamber into the flank always resulted in tumour regrowth, confirming the presence of viable
tumour cells following photodynamic therapy (PDT). When the chamber was left intact, the light dose of
450 Jcm2 yielded complete tissue necrosis. The role of the dye-carrier complex in shielding the vascular
surrounding from photoproducts was studied in a third group of animals. The presence of peroxides was
demonstrated in the serum of these animals after PDT with zinc phthalocyanine in liposomes (ZnPc-lip) using
a total light dose of 450 J cm-2. This ex vivo observation supports the previously reported observations in vitro
that the carrier complex is able to quench the photoproducts resulting from photoactivation of the photosen-
sitiser which is present in the circulation.
In photodynamic therapy (PDT) the goal is to achieve
tumour necrosis with minimal damage to normal tissue using
local activation by light of a photosensitiser that is retained
in the target tissue. PDT is currently undergoing clinical
evaluation with Photofrin as photosensitiser, which is a
preparation obtained from haematoporphyrin derivative
(HPD) and enriched in the active fraction.
Phthalocyanines are being investigated as alternative
photosensitisers for PDT (Ben-Hur & Rosenthal, 1986). They
are structurally similar to porphyrins but in contrast have a
high extinction coefficient in the 670-690 nm range. At this
wavelength, tissue penetration of light is deeper than at
630 nm where porphyrins are excited.
Phthalocyanines have a flat aromatic macrocycle, which
makes these compounds poorly water soluble. Adding sul-
phonic acid groups to the molecule (Brasseur et al., 1987)
yields photodynamically active, water-soluble derivatives.
Their synthesis is relatively easy, but the subsequent
purification can be quite elaborate. Cutaneous photosen-
sitivity resulting from phthalocyanine administration is
reported to be much less than from Photofrin (Tralau et al.,
1989). The dye is stable in a biological environment and
shows fluorescence in its monomeric, active form. Its
fluorescence can therefore be exploited for tumour-localising
purposes but, in contrast to Photofrin, it also gives inform-
ation on local dye concentration (MacRobert et al., 1989).
Phthalocyanines have been shown to photosensitise malig-
nant cells both in vitro and in vivo [for a recent review see
Rosenthal (1991) and van Lier (1990)].
Tumour localisation of the sulphonated phthalocyanines is
greatly influenced by the lipophilic nature of the drug. The
work of others (Chan et al., 1990) and also our own observa-
tions have shown that fluorescence-based tumour localisation
of sulphonated phthalocyanines is positively correlated with
the degree of sulphonation of the phthalocyanine molecule
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(van Leengoed et al., 1993a). However, where photodynamic
activity with respect to tumour necrosis is concerned, the
degree of sulphonation is inversely related to the effect,
favouring lipophilic dyes over hydrophilic dyes (Brasseur et
al., 1988; Berg et al., 1989; van Leengoed et al., 1993b).
Instead of adding sulphonate groups to the molecule to
increase the water solubility, liposomes can be used as a
carrier system, making the lipophilic drugs suitable for
systemic administration. In vivo, liposomes associate with the
lipid core of lipoproteins. Low-density lipoproteins (LDLs)
have a particularly high affinity for tumour cells through a
receptor-mediated transport mechanism (Goldstein et al.,
1979). Liposomes have been shown to facilitate efficient
targeting in vivo by water-insoluble porphyrins (Jori et al.,
1983) as well as by Zn(II) phthalocyanine (ZnPc) (Reddi et
al., 1987) at very low dosages.
In this paper, we describe the in vivo fluorescence kinetics
of this drug-carrier complex and determine the in vivo effects
of subsequent optical irradiation on tumour necrosis using a
dorsal skinfold chamber model. The role of the vascular
effects resulting from treatment and quenching of photopro-
ducts by the carrier complex of the photosensitiser present in
the circulation will be discussed.
Materials and methods
Animal model
Female WAG/Rij rats (ITRI-TNO, Rijswijk, The Netherlands)
12-14 weeks of age were used. During a 3 week preparation
period the animals were equipped with a skinfold chamber on
their backs. The chamber includes a 0.5 mm layer of sub-
cutaneous tissue, wedged between two transparent covers. An
isogeneic mammary carcinoma was transplanted into the sub-
cutaneous tissue of the chamber. The animal model permits
observation of the pharmacokinetics of photosensitisers
based on fluorescence and the assessment of vascular effects
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resulting from photodynamic therapy (Star et al., 1986; van
Leengoed et al., 1990). Hypnorm (Janssen Pharmaceuticals,
Beerse, Belgium) was used as a general anaesthetic during all
procedures. In accordance with the Dutch law on animal
experiments, the protocol was submitted to and approved by
the animal experiments committee.
Drug-carrier system
Zn(II) phthalocyanine (Ciba-Geigy, Basle, Switzerland)
incorporated into small unilamellar liposomes was prepared
as previously described (Valduga et al., 1987). Briefly,
0.75-1 ml of a mixture of 66 LAM ZnPc in pyridine (Janssen
Pharmaceuticals) and 3.56 mM dipalmitoylphosphatidyl-
choline (DPPC) in ethanol was slowly injected into 0.9%
aqueous sodium chloride at 55°C using a microsyringe. After
spontaneous cooling to room temperature, the suspension
was dialysed for 3 h against 2 x 500 ml of 0.9% saline to
remove organic solvents. The resulting dye concentration was
measured by optical absorbance using a Lambda 5 (Perkin
Elmer) spectrophotometer (a = 2.42 x I05 M-l cm'-l at Xm.).
A calculated volume of the liposome suspension supp-
lemented with phosphate-buffered saline (PBS) was
administered via a tail vein of the animals resulting in a dye
dosage of 0.14mg perkg body weight.
Fluorescence detection
Fluorescence was excited at 610 nm with a fluence rate of
0.25 mW cm-2 and detected above 665 nm using an RG665
coloured glass filter and an intensified CCD camera.
Digitised fluorescence images obtained from the fluorescence
detection system were used to measure average greyscale
values of selected areas of interest of blood vessel, tumour
and normal tissue. To minimise individual differences these
values were used to express fluorescence of tumour tissue and
blood vessels as averaged ratios relative to normal tissue
(subcutis) values.
Experimentalprocedure
In order to establish the optimum dose for fluorescence
detection and PDT, the first series of experiments was per-
formed in a pilot study on 14 animals, varying drug dose,
light dose and interval between drug administration and
treatment. All experiments began when the tumours in the
chambers had reached a diameter of 2-3 mm. Two drug
doses were compared: 0.14mg kg-' and 0.21 mg kg-'. The
animals were anaesthetised and, following the recording of
an autofluorescence image, the dye-carrier complex was
administered via a tail vein of the animal. At 5 min and at
24 h p.i., fluorescence images were recorded. Twenty-four
hours after dye administration, a treatment light dose of 450
or 900 Jcm-' was delivered to the chamber, using an
irradiance of 100 mW cm-2 at 610 nm, obtained from an
argon ion pumped-dye laser system (Spectra Physics
171 + 375). The wavelength of 610 nm is at the fluorescence
excitation maximum closest to the fluorescence emission
wavelength of 675 nm (Figure 1). In this pilot study rhodamine
was used as the lasing dye because fluorescence was the
primary objective. With rhodamine it is not possible to
generate light of 675 nm, the wavelength at which ZnPc has
maximum light absorption. Therefore, when it was later
decided to include PDT, this was performed at 610 nm. In the
subsequent series of experiments DCM (4-dicyanomethylene-
2-methyl-6(P-dimethylaminostytyl)-4H-pyran) was used as the
lasing dye, because it allows generation of both 610 and
675 nm light (see below).
After treatment, the vascular effects were scored for a
period of 7 days using a microscope at low magnification.
After the observation period the content of the chamber was
transplanted subcutaneously into the flank of the same
animal to obtain an estimate of tumour cell viability.
All subsequent series of experiments were performed using
a drug dose of 0.14 mg kg-' (see Discussion). In a group of
six animals, fluorescence pharmacokinetics was observed at 5,
15, 30, 60, 120, 180, 240, 300 and 360 min and at 24h p.i.
Each digitised image was accompanied by a similar image of
a piece of reference material (coloured plastic). This enabled
correction of the fluorescence image for inhomogeneities in
the detection system optics and variations in laser output.
Twenty-four hours p.i. a treatment light dose of 150 Jcm2
(100 mW cm-2, 675 nm) was delivered to the chamber. Dur-
ing and after treatment, vascular effects of tumour and nor-
mal tissue were scored on a 0-8 scale. A score of 0 corres-
ponds to no observable effect on the vasculature, whereas a
score of 8 indicates no circulation. The phenomena
associated with each score have been described in a previous
paper (Van Leengoed et al., 1993b). Two hours after treat-
ment one chamber was prepared for histology and from two
animals the content of the chamber was transplanted into the
flank of the same animal. In the remaining three animals
transplantation was performed at the end of a 7 day follow-
up period during which the vascular damage was assessed
daily. In order to achieve tumour necrosis, in a third group
of six animals, the therapeutic light dose was increased to
450 Jcm2.
The role of the dye-carrier complex in shielding the vas-
cular surroundings from photodamage was studied in the
serum of a fourth group of animals. The skinfold chambers
of a group of six animals having received an i.v. dose of
0.14 mg kg-' ZnPc were irradiated 24 h p.i. with a total light
dose of 450J cm-2. Immediately after treatment the serum
was collected and stored frozen at - 20°C until it could be
tested for the presence of any products due to photosensitisa-
tion by the phthalocyanine (still detectable by means of
fluorescence in the circulation). Special attention was paid to
serum lipoproteins, which are the specific carriers of
liposome-delivered ZnPc (Reddi et al., 1990). The lipoprotein
fraction of serum proteins was separated by density-gradient
ultracentrifugation (Havel et al., 1955). The lipoproteins were
resuspended in saline and divided into two aliquots. One
aliquot was used for determining the apoprotein aromatic
amino acids after denaturation obtained by dilution with an
excess of 2% aqueous sodium dodecyl sulphate (SDS); the
measurements were performed by a MPF-4 Perkin Elmer
spectrophotofluorimeter, using an excitation wavelength of
285 nm. The second aliquot was used for evaluation of lipid
peroxidation in terms ofmalondialdehyde (MDA) formation;
this was based on the thiobarbituric (TBA) assay (Kappus,
1985) which allows quantitative measure of some decomposi-
tion products of lipid peroxides. The MDA concentration
was determined by absorbance measurements at 535 nm
using a molar extinction coefficient of 154,000 M- cm'.
Lipoprotein samples from animals that had been treated by
the same procedure but that had not been exposed to light
were analysed in parallel and used as controls.
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Figure 1 Absorption spectrum of zinc phthalocyanine in
pyridine (ZnPc concentration 0.0074mgml-'). The two excita-
tion wavelengths used in this study, 610 and 675 nm, are
indicated by arrows.842 H.L.L.M. VAN LEENGOED et al.
Table I Results of the pilot experiment performed to determine the drug and light dose and
treatment interval to be used in the main study. Treatment light of 610 nm wavelength was delivered
to the observation chamber at an irradiance of 100mWcm-2. The reason for the choice of this
wavelength is explained in the text
Number of animals Complete necrosis of
with tumour tissue in chamber for Regrowth after
ZnPc fluorescence PDT light the given interval retransplantation of
dose >subcutis at dose to treatment tumour into flank
(mgkg-') 24h p.i. (J cm-2) 24h 48h (no. of tumours)
0.14 4/4 450 0/2 -/- 2/2
900 1/2 -/- 1/2
0.21 3/10 450 1/2 1/2 2/4
900 1/4 1/2 4/6
Results
In the pilot experiments, both fluorescence excitation and
photodynamic therapy were performed using light of 610 nm
(see Materials and methods). The results of these experiments
are summarized in Table I.
Tumour fluorescence showed little selectivity with
0.21 mg kg-' ZnPc compared with 0.14mgkg-' and exceed-
ed the background in only 3 out of 10 animals. Complete
necrosis was observed at both light dosages using a drug
dose of 0.21 mg kg-', but a light dose of 900 J cm-2 was
required when a drug dose of 0.14 mg kg-' was used. When
retransplantation was done immediately following therapy,
tumour regrowth was observed with both drug doses.
Figure 2 shows digital fluorescence images of liposome-
bound phthalocyanine in the chamber model before and at
four different intervals after i.v. administration of
0.14mgkg-'. Note that the fluorescence of tumour and
blood vessel increases following administration and that even
at 24h both tumour and blood vessel fluorescence exceed
that of the normal tissue.
The fluoresence signals of tumour, blood vessel and nor-
mal tissue following i.v. administration of the drug are ex-
pressed as averaged greyscale values in Figure 3. After the
dye has been administered, fluorescence in the blood vessels
increases slowly, reaching a plateau at 120 min p.i. The
fluorescence signal then remains stable but the ratio of vessel
to subcutis starts to decline (Figure 4) because of the slow
increase of fluorescence in the normal tissue. Tumour tissue
vs normal tissue ratios increase even more slowly, reaching a
maximum value approximately 4 h p.i. Two hours p.i. a ratio
Figure 2 Digitised fluorescence images of ZnPc-lip taken before
injection (centre) and at 5 (a), 60 (b) and 360 min (c) and at 24 h
p.i. (d). Note the tumour fluorescence at 360 min and the per-
sistence of fluorescence in the circulation. In terms of average
greyscale values, fluorescence of the tumour still exceeds values of
the normal tissues at 24 h p.i. The diameter of visible tissue in the
chamber is 9 mm.
of 2 is exceeded, and this level is maintained at least over a
4 h period between 2 and 6 h p.i. From 60 min onwards and
at 24 h p.i., the fluorescence in both the tumour and the
circulation exceeds that of the normal tissue.
Twenty-four hours p.i., a treatment light dose of 150 J cm-2
(100 mW cm-2, 675 nm) was administered to the chamber.
This light dose was based on a ratio of about 6 between the
optical absorption of ZnPc at 675 and 610 nm (see also
Discussion). With this light dose complete necrosis was never
observed. Retransplantation, either 2 h after treatment or at
the end of the observation period, consistently resulted in
tumour regrowth. The presence of vital tumour cells was
confirmed by histology.
In order to achieve tumour necrosis it was decided to
increase the dose to 450 J cm-2 and the averaged circulation
damage scores of the third group of six animals are shown in
Figure 5. Using this light dose, maximum damage scores
were observed in tumour tissue starting at day 1. A small
250
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Figure 3 Fluorescence pharmacokinetics of ZnPc-lip following
i.v. administration of 0.14 mgkg' of the drug-carrier complex.
Fluorescence of the regions ofinterest ( _, tumour; E=I, vessel;
and ( , normal tissue) was measured in the digitised image for
each of the six animals and at each time point and expressed as
greyscale values. Error bars indicate s.e.m.
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Figure 4 Averaged ratios ± s.e.m. of tumour tissue (-) and
blood vessel (0) fluorescence relative to normal tissue (subcutis)
fluorescence following dye administration (0.14mgkg-').IN VIVO FLUORESCENCE AND PDT USING LIPOSOME-BOUND ZnPc 843
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Figure 5 Circulation damage scores of tumour (U) tissue and
normal (0) tissue, during and after a treatment light dose of
450 J cm~2 (100 mW cm~2, 675 nm) 24 h after i.v. administration
of ZnPc-lip. Scores range from (no observable damage) to 8 (no
observable circulation). Values are averaged over six animals and
the duration of the treatment is expressed in minutes. Zero days
post treatment indicates 2 h after the end of the irradiation,
which lasted 75 min.
recovery of the circulation in the normal tissue of one animal
resulted in a drop in the average damage score to below 8,
but the damage score in tumour tissue remained maximal
during the observation period. Complete necrosis without
recovery was observed in all three rats that were monitored
during the whole observation period. When the content of
the chamber was retransplanted 2 h after treatment, regrowth
was observed. Histology performed at the same interval
again demonstrated the presence of vital tumour cells. Dur-
ing treatment the vascular effects appeared minimal, increas-
ing only during the last 15 min of the total treatment time of
75min.
The lipoproteins isolated from the serum of a fourth group
of six animals which received ZnPc PDT with 450Jcm-2
were analysed as described in the Materials and methods
section. The 285 nm excited apoprotein fluorescence gave a
maximum at 358 nm, which is typical of tryptophyl residues
in denatured protein samples; the spectral shape and relative
fluorescence intensity were essentially identical for lipo-
proteins obtained from irradiated and unirradiated serum.
This observation strongly suggests that tryptophan, a main
target of porphyrin-photosensitised protein damage (Joni &
Spikes, 1984), is not affected under our irradiation condi-
tions. On the other hand, the analysis for lipid peroxidation
showed the formation of 3.97 1imol of MDA per lipoprotein
molecule vs a background value of 0.18 yimol of MDA found
for unirradiated serum lipoprotein.
Discussion
Hydrophobic photosensitisers like ZnPc, which have excellent
photochemical and photophysical properties for PDT, but
will aggregate and/or precipitate in an aqueous environ-
ment, can be incorporated into liposomes and administered
systemically. In this way about 30% of lipsome-bound
photosensitisers can be selectively transferred to LDLs (Joni,
1989). These lipoproteins can be endocytosed by neoplastic
cells through a specific receptor-mediated pathway. Several
malignant tissues have elevated numbers of LDL receptors
(Spikes & Joni, 1987). A large amount of drug can thus be
accumulated by the tumour tissue in spite of the low injected
doses (Reddi et at., 1987).
During the pilot experiment, laser light of 675 nm was not
available. The photosensitiser was therefore excited at
610 nm, a local maximum in the absorption spectrum (Figure
1). This wavelength was also used for fluorescence excitation.
Based on the results of this pilot study a sensitiser dose of
0.14 mg kg' was selected as optimal to study both fluor-
escence pharmacokinetics and photodynamic effects of the
drug-carrier complex. Although a larger photosensitiser dose
was expected to result in increased phototoxicity, the increase
in normal tissue fluoresence using 0.21 mg kg-' had an
adverse effect on the tumour to normal tissue fluorescence
ratio. The sensitiser dose of 0.14mgkg-' in combination
with treatment light of 610nm and a total light dose of
900 J cm-2 was sufficient to cause tumour necrosis. This light
dose was rather high but should be viewed with regard to the
low extinction coefficient of ZnPc at this wavelength (see
below for 675 nm).
Phthalocyanine fluorescence can be employed as a diagnos-
tic tool to monitor the presence of the photosensitiser in its
monomeric, active state (MacRobert et al., 1989). Detecting
HPD or Photofrin in this way is more complicated because
these drugs contain a number of components with different
relationships between fluorescence and photodynamic
activity.
After administration of the dye-liposome complex, a
gradual accumulation of fluoresence in the circulation as well
as in the tumour (Figure 3) is observed. When studying
sulphonated phthalocyanines in the same chamber model, a
fluorescent angiogram with the highest intensity in this cir-
culation is usually observed immediately p.i., followed by a
gradual decrease of the fluorescence in time (van Leengoed et
al., 1990). However, the fluorescence in the circulation
reached its peak only 120 min p.i. using liposomal ZnPc. This
increase in the fluorescence in the circulation till 120 min p.i.
might be explained by considering the self-quenching of
fluorescence owing to the relatively high concentration of the
photosensitiser in the carrier system. This increase in
fluorescence could represent the release process by the carrier
system of the photosensitiser similar to that which has been
described for fluorescein (Weinstein et al., 1977).
The fluorescence signal in tumour tissue increases even
more slowly than the fluorescence in the circulation. This
observation probably relates to the fact that the liposome-
bound ZnPc is taken up by lipoproteins before being
accumulated by the tumour cells through an active process.
Between 3 and 5 h p.i. the tumour fluorescence exceeds a
ratio of 2 (Figure 4), making it easily detectable against the
normal tissue fluoresence, which hardly increases during this
interval. This interval could therefore be utilised as a window
for tumour detection. The limited increase in fluorescence in
the normal tissue also contributes to the fact that at 24 h p.i.
both tumour and blood vessel fluorescence remains detect-
able. When tested in the same tumour model system at 24 h
p.i., HPD and Photofrin fluorescence usually appeared lower
in the tumour than in the surrounding normal tissue (Van
Leengoed et al., 1990).
Exciting the photosensitiser at 610 nm with 900 J cm-2
resulted in tumour necrosis in one out of two animals using a
sensitiser dose of 0.14 mg kg-'. When the sensitiser was
excited at 675 nm, a 6-fold reduction in the total light dose to
150 Jcm2 was expected to yield similar results. This idea
was based on the fact that, in pyridine, phthalocyanine
absorption at 675 nm appeared at least 6-fold larger than at
620 nm (Figure 1). Actually, using this light dose, 1 day after
treatment the vasculature of the normal tissue was already
recovering and tumour regrowth was always observed.
Tumour necrosis was achieved when a light dose of 450 J
cm 2 was used, but this light dose also caused a maximal
effect on the normal tissue circulation. To explain these
observations we propose that in vivo aggregation of the dye
may occur, and this will result in a reduction of the
differences in optical absorption as a function of wavelength.
A drug dose of 0.14mgkg-' can be considered very low
compared with the dose of Photofrin (10 mg kg-') or sul-
phonated phthalocyanines (2.5-5 mg kg-') used in the
experiments with rats. The fact that tumour necrosis was
observed with this low drug dose suggests that the targeting
of the photosensitiser using liposomes as carriers is effective.
Targeting of the photosensitiser towards individual tumour
cells is expected to result in more direct cell kill (Zhou et al.,
1988). However, from our data it appears that the number of
tumour cells killed directly is not sufficient for tumour con-
trol. Retransplantation immediately after treatment always
resulted in tumour regrowth. Moreover, viable tumour cells844 H.L.L.M. VAN LEENGOED et al.
were confirmed histologically 2 h after treatment. Tumour
cell kill cannot be quantified using our method. It only
allows the demonstration of the presence or absence of
tumour cells capable of causing tumour regrowth. Tumour
control by PDT with ZnPc-lip therefore probably requires
vascular damage in a margin of normal tissue around the
tumour.
During the first 5min of illumination, vasospasm of
arteries was the most striking vascular effect that was
observed. This vasospasm usually disappeared within the first
30 min of irradiation. In comparable experiments using sul-
phonated phthalocyanines similar vasospasm of the arteries
was observed. These effects were stronger using dyes chelated
with zinc as a central metal ion rather than with aluminium.
The vasospasms were considered to cause hypoxia and,
assuming that oxygen is indispensable for Pc-PDT (Bown et
al., 1986), thereby negatively influence the effectiveness of the
photochemical reaction. Using liposome-bound ZnPc it
seems that after the initial response of the artery to the
treatment arterial blood supply is restored till the end of
treatment. During the period of illumination no thrombi or
vasoconstriction of the larger veins could be observed. By the
end of the treatment period stasis was observed pre-
dominantly in the capillary bed of both tumour and sur-
rounding normal tissue. However, judging from the initial
vasospasms and damage to the capillary bed, the endo-
thelium is likely to be a target for PDT using ZnPc-lip. These
findings agree with what has been found by Milanesi et al.
(1987) and Evensen (1983). The vascular effects reach their
maximum values between 2 h post therapy and day 1 (Figure
4) and cannot be distinguished from the inflammatory re-
sponse to the treatment.
At day 1, fluorescence in the blood vessels was clearly
distinguishable from the normal tissue, so that active
photosensitisers appear to be present in the circulation. In
view of this observation, the vascular effects observed were
much less than expected. This could well be a consequence of
a protective action performed by the lipoprotein carrier of
ZnPc. The close spatial interrelation between the photosen-
sitiser and unsaturated lipids in the large lipid moiety of
lipoproteins should favour a preferential attack of the
photogenerated reactive transients (e.g. singlet oxygen or
radical species on intramolecular targets, thus reducing the
concentration of toxic intermediates available for attacking
the vessel wall. In other words, lipoprotein carriers might act
as a quencher in the photochemical process, as has been
shown earlier in vitro for porphyrin photosensitisation of
LDLs. (Candide et al., 1988; Maziere et al., 1990).
The study presented in this paper describes the
fluorescence pharmacodynamics and vascular damage follow-
ing photodynamic therapy using phthalocyanine administered
in liposomes. Because of this combination we were not able
to study the fluorescence kinetics beyond 24 h p.i. and
therefore do not know how quickly the dye is eliminated
from the tumour tissue. By combing the study of fluorescence
and PDT we meant to obtain as much information as possi-
ble with a limited number of experimental animals, consider-
ing that the model is quite laborious. We chose to treat at the
rather common interval of 24 h p.i. Based on the information
available now and described in this paper it should be worth-
while to set up new experiments to study the fluorescence
kinetics over longer time periods after drug administration
and also to study the effects of PDT performed at the time of
the highest fluorescence ratio between tumour and normal
tissues.
This work was supported by the Dutch Cancer Society ('Koningin
Wilhelmina Fonds), Project DDHK-89-3. Funds for equipment were
granted by the 'Maurits and Anna de Kock Stichting', the 'Nijbak-
ker Morra Stichting' and the 'Josephine Nefkens Stichting'. The
authors wish to thank Dennes van der Wel for preparing the photo-
graphs.
Abbreviations: HPD, haematoporphyrin derivative; i.v. intravenous;
LDL, low-density lipoprotein; MDA, malondialdehyde; PDT,
photodynamic therapy; p.i., post injection; ZnPc-lip; zinc
phthalocyanine in liposomes.
References
BEN-HUR, E. & ROSENTHAL, I. (1986). Action spectrum
(600-700 nm) for chloraluminum phthalocyanine induced
photoxicity in chinese hamster cells. Lasers Life Sci., 1, 79-86.
BERG, K., BOMMER, J.C. & MOAN, J. (1989). Evaluation of sul-
phonated aluminium phthalocyanines for use in photo-
chemotherapy. Cellular uptake studies. Cancer Lett., 44, 7-15.
BOWN, S.G., TRALAU, C.J., COLERIDGE-SMITH, P.D., AKDEMIR, D.
& WIEMAN, T.J. (1986). Photodynamic therapy with porphyrin
and phthalocyanine sensitization: quantitative studies in normal
rat liver. Br. J. Cancer, 54, 43-52.
BRASSEUR, N., ALI, H., LANGLOIS, R., WAGNER, R., ROUSSEAU, J.
& VAN LIER, J.E. (1987). Biological activities of phthalocyanines.
V. Photodynamic therapy of EMT-6 mammary tumors in mice
with sulphonated phthalocyanines. Photochem. Photobiol., 45,
581-586.
BRASSEUR, N., ALI, H., LANGLOIS, R. & VAN LIER, J.E. (1988).
Biological activities of phthalocyanines. IX. Photosensitization of
V-79 chinese hamster calls and EMT-6 mouse mammary tumor
by selectively sulphonated zinc phthalocyanines. Photochem.
Photobiol., 47, 705-711.
CANDIDE, C., REYFTMANN, J., SANTUS, R., MAZIERE, J.C., MOR-
LIERE, P. & GOLDSTEIN, S. (1988). Modification of epsilon-
amino groups of lysines, cholesterol oxidation and oxidized
lipid-apoprotein cross-link formation by porphyrin-
photosensitized oxidation of human low density lipoproteins.
Photochem. Photobiol., 48, 137-146.
CHAN, W., MARSHALL, J., SVENSEN, R., BEDWELL, J. & HART, I.R.
(1990). Effect of sulphonation on the cell and tissue distribution
of the photosensitiser aluminium phthalocynaine. Cancer Res.,
50, 4533-4538.
EVENSEN, J.F., GALDAL, K.K. & NILSEN, E. (1983). LDL-induced
cytotoxicity and its inhibition by anti-oxidant treatment in cul-
tured endothelial cells and fibroblasts. Atheroschlerosis, 49,
23-30.
GOLDSTEIN, J.L., ANDERSON, R.G.W. & BROWN, M.S. (1979).
Coated pits, coated vesicles and receptor-mediated endocytosis.
Nature, 279, 679-685.
HAVEL, R.J., EDER, H.A. & BRAGDON, J.H. (1955). Distribution and
chemical composition of ultracentrifugally separated lipoproteins
in human serum. J. Clin. Invest., 34, 1345-1353.
JORI, G., TOMIO, L., REDDI, E., ROSSI, E., CORTI, L., ZORAT, P.L. &
CALZAVARA, F. (1983). Preferential delivery of liposome-
incorporated porphyrins to neoplastic cells in tumor-bearing rats.
Br. J. Cancer, 48, 307-309.
JORI, G. & SPIKES, J.D. (1984). Photochemistry of porphyrins. In
Topics in Photomedicine, Smith, K. (ed.) pp. 193-212. Plenum
Press: New York.
JORI, G. (1989). In vivo transport and pharmacokinetic behaviour of
tumour photosensitizers. In Photosensitizing Compounds: their
Chemistry, Biology and Clinical Use. Bock, G. & Harnett, S.
(eds.) pp. 78-86. (Ciba Foundation Symposium 146). John
Wiley: Chichester.
KAPPUS, H. (1985). Lipid peroxidation: mechanisms analysis,
enzymology and biological relevance. In Oxidative Stress, Sies, H.
(ed.) pp. 273-310. Academic Press: New York.
MACROBERT, A.J., BOWN, S.G. & PHILLIPS, D. (1989). What are the
ideal photoproperties for a sensitizer? In Photosensitizing Com-
pounds: their Chemistry, Biology and Clinical Use, Bock, G. &
Harnett, S. (eds.) pp. 4-16. (Ciba Foundation Symposium 146).
John Wiley: Chichester.
MAZIERE, J.C., SANTUS, R., MORLIERE, P., REYFTMANN, J., CAN-
DIDE, C., MORA, L., SALMON, S., MAZIERE, C., GATT, S. &
DUBERTRET, L. (1990). Cellular uptake and photosensitizing
properties of anticancer porphyrins in cell membranes and low
and higher density lipoproteins. J. Photochem. Photobiol. B:
Biology, 6, 61-68.IN VIVO FLUORESCENCE AND PDT USING LIPOSOME-BOUND ZnPc 845
MILANESI, C., BIOLO, R., REDDI, E. & JORI, G. (1987). Ultrastruc-
tural studies on the mechanism of the photodynamic therapy of
tumors. Photochem. Photobiol., 46, 675-682.
REDDI, E., LO CASTRO, G., BIOLO, R. & JORI, G. (1987). Phar-
macokinetics studies with zinc(II)phthalocyanine in tumour bear-
ing mice. Br. J. Cancer, 56, 597-600.
REDDI, E., ZHOU, C., BIOLO, R., MENEGALDO, E. & JORI, G. (1990).
Liposome or LDL administered Zn(II)phthalocyanine as a
photodynamic agent for tumours. I. Pharmacokinetic properties
and therapeutic efficiency. Br. J. Cancer, 61, 407-411.
ROSENTHAL, I. (1991). Phthalocyanines as photodynamic sensitizers.
Photochem. Photobiol., 53, 859-870.
SPIKES, J.D. & JORI, G. (1987). Photodynamic therapy of tumours
and other diseases. Lasers Med. Sci., 2, 3-15.
STAR, W.M., MARIJNISSEN, J.P.A., VAN DEN BERG-BLOK, A.E., VERS-
TEEG, A.A.C., FRANKEN, N.A.P. & REINHOLD, H.S. (1986). Dest-
ruction of rat mammary tumor and normal tissue microcircula-
tion by hematoporphyrin derivative photoradiation observed in
vivo in sandwich observation chambers. Cancer Res., 46,
2532-2540.
TRALAU, C.J., YOUNG, A.R., WALKER, N.P.J., VERNON, D.I., MAC-
ROBERT, A.J., BROWN, S.B. & BOWN, S.G. (1989). Mouse skin
photosensitivity with dihaematoporphyrin ether (DHE) and
aluminium sulphonated phthalocyanine (AIISPc): a comparative
study. Photochem. Photobiol., 49, 305-312.
VALDUGA, G., REDDI, E. & JORI, G. (1987). Spectroscopic studies on
Zn(II)-phthalocyanine in homogeneous and microheterogeneous
systems. J. Inorg. Biochem., 29, 59-65.
VAN LEENGOED, E., VERSTEEG, A.A.C., VAN DER VEEN, N., VAN DEN
BERG-BLOK, A.E., MARIJNISSEN, J.P.A. & STAR, W. (1990).
Tissue-localizing properties of some photosensitizers studied by in
vivo fluorescence imaging. J. Photochem. Photobiol. B: Biology, 6,
111-119.
VAN LEENGOED, H.L.L.M., VAN DER VEEN, N., VERSTEEG, A.A.C.,
OUELLET, R., STAR, W. & VAN LIER, J.E. (1993a). In vivo
fluorescence kinetics of phthalocyanines in a skin-fold observa-
tion chamber model: role of central metal ion and degree of
sulfonation. Photochem. Photobiol., 58, 233-237.
VAN LEENGOED, H.L.L.M., VAN DER VEEN, N., VERSTEEG, A.A.C.,
OUELLET, R., VAN LIER, J.E. & STAR, W.M. (1993b). In vivo
photodynamic effects of phthalocyanines in a skin-fold observa-
tion chamber model: Role of central metal ion and degree of
sulphonation. Photochem. Photobiol., 58, 575-580.
VAN LIER, J.E. (1990). Phthalocyanines as sensitizers for PDT of
cancer. In Photodynamic Therapy of Neoplastic Disease. Vol. 1,
Kessel, D. (ed.) pp. 279-290. CRC Press: Boston.
WEINSTEIN, J.N., YOSHIKAMI, S., HENKART, P., BLUMENTHAL, R.
& HAGINS, W.A. (1977). Liposome cell interaction: transfer and
intracellular release of a trapped fluorescent marker. Science, 195,
489-491.
ZHOU, C., MILANESI, C. & JORI, G. (1988). An ultrastructural com-
parative evaluation of tumors photosensitized by porphyrins
administered in aqueous solution, bound to liposomes or to
lipoproteins. Photochem. Photobiol., 48, 487-492.